Literature DB >> 16771862

Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha.

Hillary D Lum1, Ilia N Buhtoiarov, Brian E Schmidt, Gideon Berke, Donna M Paulnock, Paul M Sondel, Alexander L Rakhmilevich.   

Abstract

Effector cells of the innate immune system have diverse functions that can result in tumour inhibition or tumour progression. Activation of macrophages by CD40 ligation has been shown to induce antitumour effects in vitro and in vivo. Here we investigated the role of nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha) as mediators in the tumoristatic effects of murine peritoneal macrophages activated with agonistic anti-CD40 monoclonal antibody (alphaCD40) alone and following further stimulation with bacterial lipopolysaccharide (LPS). We found that macrophages activated in vivo by alphaCD40 exhibited tumoristatic activity in vitro against B16 melanoma cells; the tumoristatic effect correlated with the level of NO production and was enhanced by LPS. Use of the NO inhibitor L-nitro-arginine-methyl esterase (L-NAME) and evaluation of macrophages from inducible NO synthase (iNOS)-knockout (KO) mice following alphaCD40 activation showed reduced tumoristatic activity. CD40 ligation enhanced expression of TNF-alpha. Macrophage tumoristatic activity following alphaCD40 treatment was reduced by TNF-alpha mAb or use of macrophages from TNF-alpha-KO mice. However, further stimulation of alphaCD40-activated macrophages with LPS resulted in strong tumoristatic activity that was much less dependent on NO or TNF-alpha. Taken together, these results suggest that NO and TNF-alpha are involved in, but not solely responsible for, the antitumour effects of macrophages after activation by CD40 ligation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16771862      PMCID: PMC1782283          DOI: 10.1111/j.1365-2567.2006.02366.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.

Authors:  J G Turner; A L Rakhmilevich; L Burdelya; Z Neal; M Imboden; P M Sondel; H Yu
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

2.  The role of CD40L in T cell-dependent nitric oxide production by murine macrophages.

Authors:  A W Bingaman; T C Pearson; C P Larsen
Journal:  Transpl Immunol       Date:  2000-11       Impact factor: 1.708

Review 3.  The mononuclear phagocyte system revisited.

Authors:  David A Hume; Ian L Ross; S Roy Himes; R Tedjo Sasmono; Christine A Wells; Timothy Ravasi
Journal:  J Leukoc Biol       Date:  2002-10       Impact factor: 4.962

Review 4.  A potential role of macrophage activation in the treatment of cancer.

Authors:  A H Klimp; E G E de Vries; G L Scherphof; T Daemen
Journal:  Crit Rev Oncol Hematol       Date:  2002-11       Impact factor: 6.312

5.  CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide.

Authors:  Mihai G Netea; Jos W M van der Meer; Ineke Verschueren; Bart Jan Kullberg
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

6.  A pathway through interferon-gamma is the main pathway for induction of nitric oxide upon stimulation with bacterial lipopolysaccharide in mouse peritoneal cells.

Authors:  Motohiro Matsuura; Shinji Saito; Yoshikazu Hirai; Haruki Okamura
Journal:  Eur J Biochem       Date:  2003-10

Review 7.  Derangement of immune responses by myeloid suppressor cells.

Authors:  Paolo Serafini; Carmela De Santo; Ilaria Marigo; Sara Cingarlini; Luigi Dolcetti; Giovanna Gallina; Paola Zanovello; Vincenzo Bronte
Journal:  Cancer Immunol Immunother       Date:  2003-10-30       Impact factor: 6.968

8.  Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.

Authors:  Kangla Tsung; James P Dolan; Ying L Tsung; Jeffrey A Norton
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

Review 9.  Inflammatory cells and cancer: think different!

Authors:  L M Coussens; Z Werb
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

Review 10.  The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.

Authors:  L Bingle; N J Brown; Claire E Lewis
Journal:  J Pathol       Date:  2002-03       Impact factor: 7.996

View more
  27 in total

1.  Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Authors:  Ilia N Buhtoiarov; Paul M Sondel; Jon M Wigginton; Tatiana N Buhtoiarova; Eric M Yanke; David A Mahvi; Alexander L Rakhmilevich
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

2.  Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Ilia N Buhtoiarov; Paul M Sondel; Alexander L Rakhmilevich; Erik A Ranheim
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

3.  Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.

Authors:  Xiaoyi Qu; Mildred A R Felder; Zulmarie Perez Horta; Paul M Sondel; Alexander L Rakhmilevich
Journal:  Int Immunopharmacol       Date:  2013-11-04       Impact factor: 4.932

Review 4.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

Review 5.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

6.  Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Authors:  Timothy M Illidge; Jamie Honeychurch; Simon J Dovedi; Grazyna Lipowska-Bhalla; Stephen A Beers; Eleanor J Cheadle; Lijun Mu; Martin J Glennie
Journal:  Cancer Immunol Res       Date:  2016-05-30       Impact factor: 11.151

7.  Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.

Authors:  Yongyu Shi; Mildred A R Felder; Paul M Sondel; Alexander L Rakhmilevich
Journal:  Mol Immunol       Date:  2015-03-28       Impact factor: 4.407

8.  Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.

Authors:  Alexander L Rakhmilevich; Mark J Baldeshwiler; Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Nicholas A Kalogriopoulos; David S Koslov; Nico Van Rooijen; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-03-06       Impact factor: 6.968

Review 9.  Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.

Authors:  Jacob L Goldberg; Paul M Sondel
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

10.  Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.

Authors:  Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Paul M Sondel; Alexander L Rakhmilevich
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.